Candriam S.C.A. Kura Oncology, Inc. Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

A detailed history of Candriam S.C.A. transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 422,652 shares of KURA stock, worth $3.49 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

422,652

Previous 906,482 53.37%

Holding current value

$3.49 Million

Previous $17.7 Million 79.22%

% of portfolio

0.02%

Previous 0.1%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	SELL	$8.51 - $19.21 $4.12 Million - $9.29 Million	-483,830 Reduced 53.37%	422,652 $3.68 Million
Q2 2024 Aug 05, 2024	BUY	$17.53 - $22.98 $4.47 Million - $5.86 Million	255,065 Added 39.16%	906,482 $18.7 Million
Q1 2024 May 03, 2024	BUY	$13.42 - $23.53 $1.48 Million - $2.59 Million	110,000 Added 20.32%	651,417 $13.9 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $1.14 Million - $2.16 Million	-150,005 Reduced 21.7%	541,417 $7.79 Million
Q2 2023 Aug 08, 2023	SELL	$9.62 - $13.99 $1.18 Million - $1.72 Million	-122,942 Reduced 15.1%	691,422 $7.32 Million
Q4 2022 Feb 13, 2023	BUY	$11.23 - $16.9 $1.33 Million - $2.01 Million	118,789 Added 17.08%	814,364 $10.1 Million
Q3 2022 Nov 10, 2022	BUY	$12.01 - $19.45 $3.09 Million - $5 Million	257,260 Added 58.69%	695,575 $9.5 Million
Q1 2022 May 13, 2022	SELL	$11.78 - $16.98 $5.53 Million - $7.97 Million	-469,118 Reduced 51.7%	438,315 $7.05 Million
Q4 2021 Feb 10, 2022	SELL	$12.22 - $19.57 $475,651 - $761,742	-38,924 Reduced 4.11%	907,433 $12.7 Million
Q2 2021 Jul 20, 2021	BUY	$20.85 - $29.88 $356,118 - $510,350	17,080 Added 1.84%	946,357 $19.7 Million
Q1 2021 Apr 29, 2021	SELL	$24.75 - $39.14 $123 - $195	-5 Reduced -0.0%	929,277 $29.2 Million
Q4 2020 Jan 22, 2021	BUY	$29.0 - $41.62 $11.3 Million - $16.2 Million	390,086 Added 72.35%	929,282 $30.4 Million
Q3 2020 Oct 19, 2020	BUY	$16.3 - $30.64 $4.88 Million - $9.18 Million	299,492 Added 124.94%	539,196 $16.5 Million
Q2 2020 Jul 23, 2020	BUY	$7.95 - $18.81 $1.91 Million - $4.51 Million	239,704 New	239,704 $3.91 Million
Q4 2019 Jan 21, 2020	SELL	$12.97 - $15.94 $1.79 Million - $2.2 Million	-138,100 Closed	0 $0
Q3 2019 Oct 21, 2019	SELL	$14.75 - $20.87 $3.3 Million - $4.67 Million	-224,000 Reduced 61.86%	138,100 $2,000
Q2 2019 Aug 01, 2019	SELL	$14.71 - $19.79 $498,669 - $670,881	-33,900 Reduced 8.56%	362,100 $7.1 Million
Q1 2019 May 02, 2019	BUY	$13.73 - $16.87 $411,900 - $506,100	30,000 Added 8.2%	396,000 $6.57 Million
Q3 2018 Nov 07, 2018	SELL	$16.65 - $21.85 $266,400 - $349,600	-16,000 Reduced 4.19%	366,000 $6.41 Million
Q2 2018 Aug 14, 2018	SELL	$14.8 - $18.8 $44,400 - $56,400	-3,000 Reduced 0.78%	382,000 $6.95 Million
Q1 2018 May 09, 2018	SELL	$14.5 - $23.4 $1.89 Million - $3.04 Million	-130,000 Reduced 25.24%	385,000 $7.22 Million
Q4 2017 Feb 07, 2018	SELL	$13.5 - $16.65 $337,500 - $416,249	-25,000 Reduced 4.63%	515,000 $7.88 Million
Q3 2017 Nov 03, 2017	BUY	$6.05 - $14.95 $3.27 Million - $8.07 Million	540,000	540,000 $8.07 Million

Others Institutions Holding KURA

# of Institutions

193

Shares Held

77.5M

Call Options Held

103K

Put Options Held

106K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $552M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account